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Abstract 
Synthesis of Functionalized Benzoxaboroles 
Sravan K. Jonnalagadda 
Master of Science (Department of Chemistry and Biochemistry),  
University of Minnesota.  
2-Formylphenylboronic acids upon reaction with activated olefins such as 
acrylates, methyl vinyl ketone, and acrylonitrile, etc. via Baylis-Hillman reaction to 
provide functionalized benzoxaboroles. The corresponding homologated 
benzoxaboroles were synthesized via Barbier allylation reaction of 2-
formylphenylboronic acids with α-bromomethylacrylates. Several novel 
benzoxaborole derivatives were synthesized starting from 2-formylphenylboronic 
acid utilizing Passerini reaction and aldol reaction protocols as the key step.  
An efficient methodology for the preparation of α-hydroxyamides via boric 
acid mediated addition of isonitriles on to aldehydes has been developed. The 
reaction of isonitriles with α-boronobenzaldehyde takes place under 
intramolecular catalysis conditions to provide functionalized benzoxaboroles. 
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Chapter 1: Benzoxaboroles 
Introduction 
Boron is the fifth element in the periodic table. Boron containing 
compounds have been highly utilized in several household purposes such as 
cleaning, insecticide and medicinal uses such as antiseptic, antibacterial, multiple 
enzyme inhibitors1,2, etc. Boron containing compound, bortezomib, is a novel 
chemotherapeutic for multiple myeloma3. Apart from these medicinal uses, 
several boranes had been utilized in boron-neutron capture therapy in cancer 
treatment4. In industry, it is especially utilized in nuclear power plants as a poison 
to reduce the rate of fission. In material science, boron in the form of borates has 
been utilized in semiconductors. 
Apart from boric acid and some other borates, most of the synthetic boron 
compounds are air sensitive with a few exceptions such as sodium borohydride. 
Benzoxaboroles 1 are cyclic hemiesters of phenylboronic acids5 which are stable 
compared to the acyclic boronic acids. There are only few scientists working on 
the synthesis of these hemiesters. Despite benzoxaborole had been known for 
~60 years, these compounds are routinely used in cross coupling reactions in 
organic synthesis1.  
Benzoxaboroles also gained reputation for its medicinal usage6. For 
example, AN2728 2 is used as anti-inflammatory activity against psoriasis, a 
common skin disease. 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, 
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AN2690 3, is a broad-spectrum antifungal drug. 5-chloro-substituted 
benzoxaborole, AN2718 4, is being developed for the topical treatment of tinea 
pedis infection (Figure 1). 
 
Figure 1 Functionalized Benzoxaboroles 
   In material science, benzoxaboroles has been used in the construction of 
molecular receptors, design of self-assembled molecular structures, building 
blocks in crystal engineering, use as steroid conjugates for molecular imprinting, 
dyes, biosensors of α-hydroxy-carboxylic acids, and biocides for plastic 
biodegradation etc.7 Because of the sugar-like structures, benzoxaboroles have 
been found to selectively complex with natural oligosaccharides to effect direct 
glycosidation. They are known for their selective recognition of cell surface 
glycoconjugates.8 
The following are some of the synthetic methods that have been reported 
for the preparation of benzoxaboroles and their development as medicinal 
agents. 
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2-Methylphenylboronic acid 5 was brominated using N-bromosuccinimide, 
followed by hydrolysis of the bromide 6 to benzyl alcohol intermediate 7, which 
upon intramolecular esterification yielded unsubstituted benzoxaborole 1 
(Scheme 1.1).9 
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Scheme-1.1 Synthesis of benzoxaborole 
 
Hydrolysis of 1,2-dihydro-1-hydroxy-2,3,1-benzodiazaborines 8 in 
presence of aqueous sodium hydroxide furnished corresponding benzoxaboroles 
9 (Scheme 1.2).10 
 
 
Scheme-1.2 Synthesis of substituted benzoxaborole 
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3-substituted benzoxaboroles 10 were obtained upon the treatment of o-
formylphenylboronic acid 11 with nucleophiles such as malonic acid, 
nitromethane, sodium cyanide, etc. (Scheme 1.3).11 
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Scheme-1.3 Synthesis of 3-substituted benzoxaborole 
 
Multicomponent coupling of alkynes in presence of a transition metal 
catalyst resulted in cyclotrimerization of alkynes furnishing substituted 
benzoxaboroles 12 (Scheme 1.4).12 
 
 
Scheme-1.4 Synthesis of benzoxaborole via multicomponent coupling of 
alkynes 
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Hydroxybenzboroxole 16 was synthesized and used as common 
intermediate in the preperation of various aryl ethers. These ethers have been 
evaluated as potential anti-Trypsnosomal agents. The formyl group in 2-bromo-4-
fluorobenzaldehyde was protected with ethylene glycol as its acetal 13.  
Nucleophilic displacement of fluoride with benzyl alcohol furnished 2-(4-
(benzyloxy)-2-bromophenyl)-1,3-dioxolane 14. Reaction of 14 with n-butyl lithium 
followed by triisopropylborate, resulted in the formation of boronic acid, which 
upon acidification resulted in the deprotection of the acetal-protecting group to 
furnish the aldehyde 15. Reduction of 15 with NaBH4 yielded 6-(O-benzyl)-
benzoxaborole, which was further reduced with Pd/C to obtain 6-hydroxy-
benzoxaborole 16 (Scheme 1.5).13 
 
Scheme-1.5: Synthesis of benzoboroxoles as anti-trypanosomal agents 
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Hydroxybenzoxaborole 16 was coupled to corresponding benzyl 
bromides, alkyl bromides, or α-bromoacetates in presence of sodium hydride at 
0oC to obtain the benzyl ethers, alkyl ethers and α-alkoxyacetates respectively. 
Diaryl ethers 17 were prepared from 16 upon reaction with NaH at 70oC. 
Treatment of 16 with α-bromoacetamides in the presence of K2CO3 with NaI as 
catalyst yielded α-bromoacetamides 18. Carbamates were prepared from 16 by 
coupling with corresponding isocyanates in the presence of Et3N in DMF at 0oC 
(Scheme 1.6).13 
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Scheme-1.6: Synthesis of benzoxaboroles as anti-trypanosomal agents 
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Kim et. al. reported the synthesis of polymers of benzoxaboroles as 
monosaccharide-responsive release of insulin from polymersomes of 
polyboroxole block copolymers at neutral pH (Scheme 1.7).  The synthesis was 
initiated via the treatment of 3-bromo-4-(bromomethyl)benzonitrile 19 with 
calcium carbonate in presence of water-dioxane at 100oC to obtain 3-bromo-4-
(hydroxymethyl) benzonitrile. The hydroxy group was protected by tert-
butyldimethylsilyl (TBDMS-Cl) group and the reduction of cyanide with DiBAl-H 
furnished the aldehyde 20. Wittig olefination of 20 with 
methyltriphenylphosphonium bromide followed by the deprotection of TBDMS 
and re-protection using methoxymethyl (MOM) chloride furnished MOM ether 21. 
The aryl bromide was converted into its Grignard by reacting with magnesium at 
60oC and subsequently treated with trimethylborate to furnish the benzoxaborole 
monomer upon acidic work up in the presence of HCl.  The monomer was further 
converted into the polymer by treating 22 with xanthate 23 (Scheme 1.7).14 
 
 
Scheme-1.7: Synthesis of polymeric benzoxaboroles 
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Morpholinobenzoxaborole 24 was obtained upon the reaction of o-
formylphenylboronic acid 11 with morpholine (Scheme 1.8).15 
 
Scheme-1.8: Synthesis of 3-amino-substituted benzoxaboroles 
2-Bromo-5-fluorobenzaldehyde was reacted with sodium borohydride or 
Grignard reagents to obtain substituted alcohols 25. This was further treated with 
sodium hydride, followed by n-butyl lithium and triisopropylborate and 10% 
sulfuric acid to furnish corresponding 5-fluoro-3-substituted benzoxaboroles 26 
(Scheme 1.9).16 
 
Scheme-1.9:Practical synthesis of benzoxaboroles 
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Similarly, chiral benzoxaboroles were prepared by the reaction of 
aldehydes with asymmetric allylating reagent such as Ipc2BAllyl.  2-
bromobenzaldehyde was treated with Ipc2BAll to obtain (S)-1-(2-
bromophenyl)but-3-en-1-ol (27), which was cyclized to (S)-3-
allylbenzo[c][1,2]oxaborol-1(3H)-ol (28) upon reaction with sodium hydride, n-
butyl lithium, triisopropylborate, and sulfuric acid (Scheme 1.10).16 
 
  
Scheme-1.10: Practical synthesis of chiral benzoxaboroles 
Dimethylbromobenzene was oxidized to dicarboxylic acid using KMnO4 in 
tertiary butanol and water. Conversion of dicarboxylic acid into the corresponding 
acid chloride was achieved using thionyl chloride, which upon reaction with 
methanol in triethylamine resulted in the formation of the dimethyl ester. 
Reduction of the diester with lithium borohydride furnished the diol 29. Protection 
of the alcohol groups as THP acetal followed by the treatment with n-butyl lithium 
and triisopropylborate, and subsequent deprotection and cyclization in 6 M HCl 
furnished 5-hydroxymethylbenzoxaborole 30. This was further oxidized with PCC 
to obtain 5-formyl benzoxaborole 31. Chalcone−benzoxaborole hybrid molecules 
were prepared from this aldehyde 31 by aldol condensation with substituted 
methylketones in presence of sodium hydroxide in ethanol-water. Some of these 
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molecules showed excellent anti-trypanosomal activity aganst T. brucei with IC50 
values ranging 0.045 µg/mL (Scheme 1.11).17 
 
Scheme-1.11:Chalcone−benzoxaborole hybrid molecules as potent anti-
trypanosomal agents 
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2-bromo-5-fluorobenzaldehyde was reduced to alcohol with sodium 
borohydride in methanol. The hydroxy group was protected as the 
methoxymethyl ether (MOM) and treated with butyllithium at -78°C, in presence 
of B-phenylboronic acid ethylene glycol ester to obtain the borinic acid 32. The 
protecting group was removed under acidic conditions and the free alcohol 
spontaneously cyclized to give the target compound 33.6c Some of these 
derivatives showed antifungal properties on C. albicans at a conc of 0.25 µg/mL 
and C. neoformans at 0.5 µg/mL(Scheme 1.12). 
 
   
 
Scheme-1.12: Synthesis of AN2690 and its analogs for the potential 
treatment of onychomycosis 
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2-Bromo-3-methylbenzoic acid 34 was converted to cyano compound 35 
by amide formation followed by dehydration. Benzylic bromination on the methyl 
group with NBS followed by nucleophilic substitution with potassium acetate 
afforded the acetate 36 that upon catalytic borylation with bispinacolatodiboron in 
the presence of Pd catalyst yielded the arylboronate 37. Alkaline hydrolysis of the 
acetate followed by acidification generated the cyano benzoboroxole 38. 
Treatment of 38 with Raney nickel in aqueous formic acid gave the aldehyde 39. 
The target compound 40 was obtained by reacting the aldehyde with 2,2-
dimethyl-1,3-dioxane-4,6-dione in the presence of HCOOH and triethylamine.18  
Some of these compounds were active against malaria parasite Plasmodium 
falciparum with IC50 values in the range of 0.026 µM (Scheme 1.13). 
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Scheme-1.13: Synthesis and structure–activity relationships of novel 
benzoxaboroles as a new class of antimalarial agents 
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2-Hydroxy-4-methoxybenzaldehyde was converted to triflate 41 via 
treatment with triflic anhydride.  Catalytic borylation with bispinacolatodiboron 
provided compound 42, which was reduced with NaBH4 in methanol-THF and 
upon acid-catalyzed cyclization, was converted to 6-methoxy benzoxaborole 43. 
Demethylation of 43 with BBr3 followed by treatment with methyl 5-
chloropyrazine-2-carboxylate in potassium carbonate and DMF afforded the ester 
44, which was further hydrolyzed in basic conditions to furnish the corresponding 
carboxylic acid 45.19 Some of these compounds showed activity on E. cloacae 
P99AmpC (MIC = 1–-2 µg/mL) and E. coli SYN2549 CMY-2 (MIC = <0.5 µg/mL) 
(Scheme 1.14). 
 
 
Scheme-1.14: Synthesis and SAR of novel benzoxaboroles as a new class of 
β-lactamase inhibitors 
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Coupling of 5-amino-benzoxaborole with phenylsulfonylchloride, benzyl 
bromide and benzoyl chloride provided corresponding sulfonamide, 
aminomethylene and amide respectively and these compounds showed growth 
inhibition in T. brucei with IC50 values ranging between 0.04-1.2 µg/mL (Scheme 
1.15).20 
 
 
T. brucei Growth Inhibition IC50 = 0.02 µg/mL 
 
T. brucei Growth Inhibition IC50 = 1.21 µg/mL 
 
T. brucei Growth Inhibition IC50 = 0.04 µg/mL 
Scheme-1.15: Discovery of Novel Benzoxaborole-Based Potent 
Antitrypanosomal Agent 
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The aldehyde group of 2-bromo-5-hydroxybenzaldehyde 46 was protected 
with ethyleneglycol and treated with 4-fluorobenzonitrile to form 4-(4-bromo-3-
formylphenoxy) benzonitrile 47. Aldehyde 47 was reduced to alcohol using 
sodium borohydride and protected as a THP ether in presence of 3,4-dihydro-2H-
pyran and camphorsulfonic acid. The boron atom was then introduced by 
halogen–metal exchange with n-butyl lithium using triisopropylborate, which upon 
reaction with HCl led to the deprotection of the THP acetal and the resultant 
alcohol spontaneously cyclized to afford 4-((1-hydroxy-1,3-dihydrobenzo 
[c][1,2]oxaborol-5-yl)oxy)benzonitrile 48 (Scheme 1.16).21  This molecule showed 
activity against PDE4 (IC50 0.49 µM) and TNF-α (IC50 0.54 µM). 
 
 
Scheme-1.16: Synthesis of anti-inflammatory agent (AN2728) for the 
potential topical treatment of psoriasis and atopic dermatitis 
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3,5-dimethoxybenzyl alcohol 49 was converted to corresponding 
benzoxaborole 50 by N-iodosuccinimide iodination followed by reaction with n-
butyllithium and trimethoxyborate. Suzuki coupling of aryl iodide 51 with 
benzoxaborole 52 was facilitated by Pd(PPh3)4 catalyst in presence of sodium 
carbonate in methanol-toluene-water system at 90oC (Scheme 1.17).22 
 
 
Scheme-1.17: Suzuki coupling–macrolactamization approach to the AB-COD 
bicyclic system of vancomycin 
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6-amino-3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol acetate salt was 
treated with 2-trifluoromethyl-4-fluorobenzoyl chloride in presence of 
trimethylamine in DCM at 0oC to afford SCYX-7158 (53) (Scheme 1.18), which 
showed activity against Trypanosoma brucei rhodesiense (IC50 = 0.294 µg/mL).23 
 
 
Scheme-1.18: Synthesis of amidobenzoxaboroles 
 
 
 Owing to the importance of cyclic boronic acids, we undertook the project 
involving the development of novel methodologies for the synthesis of 
benzoxaboroles containing wide array of functional groups. Our results are 
reported in the succeeding chapters. 
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Chapter 2: Novel Methodologies for the Synthesis of Functionalized 
Benzoxaboroles  
Introduction  
Being a relatively new compound, benzoxaborole has been utilized in 
synthetic methods and applications, but most of them involve tedious synthesis 
and in almost all the cases, boron has been introduced in the very last step. 
Apart from designing novel methods for the synthesis of benzoxaborole, we 
undertook the project due to its impressive application regime in medicial 
chemistry24. In this chapter, we describe the development of three convenient, 
flexible and novel protocols for the synthesis of densely functionalized 
benzoxaboroles based on Baylis-Hillman chemistry, Barbier allylation, and aldol 
reaction protocols. In all the cases, we used 2-formyl boroaldehyde, a 
commercial available compound as a synthon. 
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Results and Discussion 
Baylis-Hillman (BH) reaction is one of the best reactions in introducing C-
C bond coupling in one step25. This reaction is atom efficient and produces 
activated allyl alcohols which are highly useful in the isomerization upon reaction 
with several nucleophiles affording valuable synthons. BH reaction usually 
involves an aldehyde and electron deficient olefin in the presence of hindered 
tertiary amine like 1,4-diazabicyclo[2.2.2]octane (DABCO). These reactions 
usually don’t require any solvent. In this case, we first utilized formylboronic acids 
5a-c as electrophiles and methyl acrylate 6a, phenyl acrylate 6b, acrylonitrile 6c, 
methyl vinyl ketone 6d, and acrolein 8 as electron deficient olefins. Aldehyde 5a 
when reacted with 2 parts of methyl acrylate in presence of 10% DABCO 
resulted in poor yields of the desired product, leaving most of the unreacted 
starting material. The yield did not improve significantly even when doubling the 
amount of the catalyst DABCO. But, with stoichiometric amount of DABCO, 
compound 7a was obtained with 58% yield after purification via silica gel column 
chromatography.  
 The above reaction with simple benzaldehyde usually requires more 
than a week for the completion. Similar reaction with 4-boronobenzaldehyde 
resulted in meagre yield even after two weeks. The increased rate of reactivity 
with 2-boronobenzaldehyde 5a could be attributed to the activation of carbonyl 
oxygen via coordination with proximal Lewis acidic boronic acid group.  
  22 
The other reactions with 5b-c with methyl acrylate was even slower (5-7 
days) because of the alkoxy substituents on the aromatic ring affording the 
products 7b-c in 54% and 56% yields respectively. Similar reactions of 5a-c with 
phenyl acrylate 6b yielded 41-45% of corresponding benzoxaboroles 7d-f 
(Scheme 2.1). 
Scheme 2.0: Baylis-Hillman Reaction 
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Scheme 2.1. Baylis Hillman reaction of β-Boronoaldehydes 
The similar BH reaction with better electron withdrawing group acrylonitrile 
6c was facile with all the boronoaldehydes 5a-c and the products 7g-i were 
obtained in moderate to good yields. Introduction of even stronger electron 
withdrawing groups resulted in poor yields of 7j-l (41-49%) due to the higher 
polymerization rate of methyl vinyl ketone 6d (Scheme 2.1). 
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We also carried out BH reaction with the aldehyde 5a and cyclohexenone 
in presence of tributylphosphene to obtain 7m in 56% yield (Scheme 2.2).  
 
Scheme 2.2: Preparation of α-cyclohexenonyl benzoxaborole 
 We also utilized acrolein 8, with boronobenzaldehyde 5a which resulted in 
9 with only 20% yield with 60% of unreacted starting material. The low yield of 9 
is due to the fact that acrolein is very sensitive monomer and susceptible for 
rapid polymerization. Longer reaction time or excessive acrolein resulted in 
polymerization of the acrolein and did not improve the yields. Hence the reaction 
was conducted in THF solvent at 0o C to minimize the polymerization. (Scheme 
2.3). 
 
Scheme 2.3. Reaction of β-Boronoaldehydes with Acrolein 
We have utilized Barbier type allylation, another C-C bond forming 
reaction involving allyl bromides and aldehydes in the presence of metals like 
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zinc and indium forming a complex with ammonium chloride to synthesize 
functionalized benzoboroxoles. We synthesized the BH derived bromides 12a-b 
by treating the corresponding aldehydes 10a and 10b with methyl acrylate 6a to 
form allylic alcohols 11a-b, followed by the reaction with HBr-H2SO4. These 
bromides were then utilized for allylation of boronobenzaldehydes 5a-c using 
Barbier allylation conditions to obtain homologated benzoxaboroles 13a-f in 
decent yields (Scheme 2.4). As expected, products had predominantly syn 
stereochemistry. The relative configuration was confirmed by single crystal X-ray 
analysis of 13d (Figure 2). 
 
Scheme 2.4. Synthesis of Homologated 0Benzoxaboroles 
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Figure 2. X-ray Crystal Structure of 13d 
We have also utilized aldol reaction with boronobenzaldehyde 5a and 
methyl ketones 14a-d to obtain β-ketobenzoxaboroles 15a-d. With bases such as 
sodium hydride, sodium hydroxide, etc., the reaction did not go to completion and 
the product was impure. When LDA is used at -78o C to generate enolate, the 
reaction resulted in aldol product 15a in 60% yield (brsm) (Scheme 2.5). Other 
substituted acetophenones such as p-nitroacetophenone, p-
bromoacetophenone, and 3,4,5-trimethoxyacetophenone upon reaction with 2-
boronobenzaldehyde resulted in corresponding products 15b-d. Irrespective of 
the amount of base used, the reaction was still incomplete with ~30-50% of 
starting material left. Benzoxaboroles 15e-g were obtained upon similar reaction 
using acetone, dimethyl and diethyl malonates with boronobenzaldehyde 6a 
which resulted in 40-62% yields (Figure 3).  
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Scheme 2.5: Synthesis of β-ketobenzoxaboroles 
 
Figure 3: β-Ketobenzoxaboroles via aldol reaction 
 All the synthesized compounds were tested for their antimicrobial efficacy 
as well as general cytotoxicity. None of the compounds exhibited any biological 
activity. This concludes that the substitution of carbon on the benzylic carbon of 
benzoxaborole lead to the loss of activity. 
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Experimental Procedures 
1. Representative procedure for the preparation of benzoxaboroles via 
Baylis-Hillman reaction 7a-l: To a stirred suspension of 2-boronobenzaldehyde 
5a (0.3 g, 2.0 mmol) and methyl acrylate 6a (0.7 mL, 8.0 mmol) was added 
DABCO (224 mg, 2.0 mmol) and stirred for 2 days at room temperature.  Upon 
completion (TLC), the reaction mixture was quenched with dilute HCl and worked 
up with ethyl acetate (3 x 10 mL).  The combined organic layers were dried 
(MgSO4), concentrated in vacuo, and purified via silica gel column 
chromatography (hexane:acetone, 3:1) to obtain 0.25 g (58%) of benzoboroxole 
7a as a white powder.  mp: 91-93oC, (Found: C, 60.62%; H, 5.25%; C12H13BO4 
requires: C, 60.60%; H, 5.09%); 1H NMR (400 MHz, CDCl3): δ 9.45 (s, 1H), 7.70-
7.72 (m, 1H), 7.40-7.44 (m, 1H), 7.25-7.35 (m, 2H), 6.16 (s, 1H), 5.93 (s, 1H), 
5.79-5.80 (m, 1H), 3.67 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 166.2, 155.5, 
140.6, 131.5, 131.2, 128.1, 126.6, 122.3, 79.3, 52.5; ESI-MS: 217 [(M-H)+, 
100%]. 
2. Representative procedure for the preparation of benzoxaboroles via 
Barbier reaction 13a-f:  To a stirred solution of 2-boronobenzaldehyde 5a (0.3 
g, 2.0 mmol) and zinc (0.19 g, 3.0 mmol), in THF (5.0 mL) was added methyl α-
bromomethylacrylate 12a (0.72 g, 4.0 mmol), and saturated NH4Cl (1 mL) and 
stirred overnight at room temperature.  Upon completion (TLC), the reaction 
mixture was filtered over celite, and worked up with water and ethyl acetate (3 x 
10 mL).  The combined organic layers were dried (MgSO4), concentrated in 
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vacuo, and purified via silica gel column chromatography (hexane:acetone, 3:1) 
to obtain 0.35 g (75%) of benzoboroxole 13a as a viscous liquid.  (Found: C, 
62.01%; H, 5.52%; C12H13BO4 requires: C, 62.11%; H, 5.65%); 1H NMR (400 
MHz, CDCl3): δ 9.24 (s, 1H), 7.67 (d, J = 7.2 Hz, 1H), 7.41-7.45 (m, 1H), 7.29-
7.36 (m, 2H), 6.12 (d, J = 1.2 Hz, 1H), 5.69 (d, J = 1.2 Hz, 1H), 5.26 (dd, J = 4.0, 
8.4 Hz, 1H), 3.64 (s, 3H), 2.89 (dd, J = 8.4, 14.4 Hz, 1H), 2.39 (dd, J = 8.4, 14.8 
Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 167.6, 156.8, 136.9, 131.2, 131.1, 128.2, 
127.9, 122.2, 79.1, 52.5, 39.2; ESI-MS: 231 (M-H)+, 189 (100%). 
3. Representative procedure for the preparation of benzoxaboroles via 
aldol reaction 15a:  To a stirred solution of acetophenone 14a (10 mmol) in 20 
mL THF was added LDA (12 mmol) at -78oC and stirred for 1 h.  A solution of 2-
boronobenzaldehyde 5a (9 mmol) in 5 mL THF was added to the reaction at -
78oC, and stirred overnight at room temperature.  Upon completion (TLC), the 
reaction was quenched with NH4Cl and worked up with ethyl acetate.  The 
combined organic layers were dried (MgSO4), concentrated in vacuo, and 
purified by silica gel column chromatography to obtain the pure benzoxaborole 
15a in 60% yield.  1H NMR (500 MHz, DMSO-d6): δ 9.21 (s, 1H), 8.03 (d, J = 8.0 
Hz, 2H), 7.74 (d, J = 7.5 Hz, 1H), 7.65-7.68 (m, 1H), 7.48-7.57 (m, 4H), 7.37-7.40 
(m, 1H), 5.71 (dd, J = 4.0, 8.8 Hz, 1H), 3.58 (dd, J = 3.5 Hz, 17.5 Hz, 1H), 3.34 
(dd, J = 8.5 Hz, 17.0 Hz, 1H); 13C NMR (125 MHz, CDCl3): 198.6, 157.5, 137.7, 
134.3, 131.6, 131.4, 129.7, 129.2, 128.2, 122.5, 77.7, 46.3; ESI-MS: 251 [(M-H)+, 
100%]. 
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Antimicrobial Assay 
Due to their importance as antimicrobial agents, the synthesized molecules have 
been evaluated for their activity as antibacterial and antifungal agents. For initial 
testing, Pseudomonas aeruginosa and Streptococcus thermophiles have been 
selected as gram negative and gram positive bacterial strains respectively. For 
antifungal activity, we chose Candida albicans and Aspergillus niger. Standard 
Kirby-Bauer disk susceptibility method was used for all the species. Mueller 
Hinton agar plates were used to grow the colonies of microbes. The microbial 
suspension was inoculated onto the agar plates and the sterile disc saturated 
with 20 µL test compound was placed on the plate. The final concentration of the 
compound was maintained at 5 and 1 µg/disc. These plated were incubated at 
37o C for 24-48 hours. The diameter of the zone of inhibition was measured in 
millimeters using calipers to determine the antimicrobial activity. None of the 
synthesized compounds showed any antimicrobial activity compared to 
compound 1, which exhibited moderate activity.  
 
Cytotoxicity Assay 
These compounds were also tested for their toxicity on MCF-7 breast cancer cell 
line using sulforhodamine-B assay. Briefly, 5 x 104 cells/mL were plated in a 48-
well plate and incubated for 18-24 hours. The test compounds were dissolved in 
DMSO and added to the wells and incubated for 3 more days. The growth media 
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was removed on the third day and the wells were washed with 1% phosphate 
buffered saline solution. The wells were dried and the SRB in 1% acetic acid was 
added. The plate was incubated for ~45 minutes and the wells were dried and 
dissolve in tris base (10mM, pH 10.2). The absorbance was recorded at 540nm, 
which gives the % survival of the cells. The assay was carried out in triplicates. 
All the compounds were tested at 100 and 50 µM. None of the synthesized 
compounds were toxic even at 100 µM concentration. This concludes that these 
molecules are generally non-toxic in nature.  
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Conclusions  
   In conclusion, we have successfully devised three methodologies using 
boronobenzaldehyde to synthesize functionalized benzoboroxoles via Baylis-
Hillman, Barbier-type allylation and Aldol chemistry. These protocols can be 
applied in the synthesis of various benzoboroxoles in large scale. The 
synthesized molecules were evaluated for their antimicrobial efficacy. These 
methodologies can be used to develop synthons for various synthetic products.  
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Chapter 3: Boric Acid Mediated Synthesis of α-Hydroxyamides and 
Synthesis of Benzoxaboroles via Passerini Reaction 
Introduction  
   Boric acid, usually available in nature in the form of borax and boracite. It 
is used for industrial as well as household purposes due to its non-toxic nature 
and it is very inexpensive. Hence, it is usually considered as a green material26. 
Various borates and organoboranes can be synthesized starting from boric acid. 
Due to the vacant orbital, it can be used as a mild Lewis acid catalyst in several 
organic reactions27.  
   Passerini and Ugi reactions are well-studied multicomponent coupling 
reactions involving aldehyde/imine, acid and isonitrile28. α-Hydroxyamides can be 
easily oxidized to prepare keto acids/amides which are biologically relevant since 
pyruvic acid is one of the important metabolites in glycolysis. Hence, α-
Hydroxyamides are important synthons for the synthesis of various agents in 
medicinal chemistry29. In this chapter, we have developed a novel methodology 
for the synthesis of several α-hydroxyamides using boric acid as a catalyst for the 
addition of isonitriles on to carbonyl compounds30.  
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Results and Discussion 
We envisioned the usage of boric acid to couple isonitriles and aldehydes 
to synthesize α-hydroxyamides. For this purpose, benzyl, cyclohexyl and tert-
butyl isonitriles 2a-c were taken as representative examples for isonitriles. 
Aldehydes 1a-g containing aliphatic, aromatic and heterocycles were utilized. For 
initial purposes, propionaldehyde and benzyl isonitrile were utilized for the 
optimization. Solvent study was conducted to figure out the suitable solvent for 
the reaction with maximum yield. Different solvents such as THF, CH2Cl2, EtOAc, 
DMF, DMSO, Dioxane, MeOH and water were used. The amount of boric acid 
was varied in each reaction to obtain decent yield. DMF and 1 equivalent of boric 
acid were found to provide α-hydroxyamides with good yields. The reaction with 
aliphatic aldehydes and aliphatic isonitriles was found to be fast with the 
generation of small amount of heat whereas the reactions with aromatic systems 
tended to be relatively slow.  
Similar reactions were performed replacing the aldehyde with ketones 
such as 3-pentanone and acetophenone. In this case, the reactions did not 
produce the product in acceptable yields even when the boric acid is increased to 
two equivalents at 80o C.   
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Table 1. Boric acid mediated addition of isonitriles and aldehydes for the 
synthesis of α-hydroxyamides. 
 
Entry Aldehyde Isonitrile Product Yield 
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  36 
6 
 
 
 
74% 
7 
 
 
 
61% 
8 
 
 
 
64% 
9 
 
 
 
72% 
10 
  
 
78% 
11 
 
 
 
74% 
12 
 
 
 
72% 
  37 
13 
 
 
 
82% 
14 
 
 
 
76% 
15 
 
 
 
80% 
16 
 
 
 
65% 
17 
 
 
 
68% 
18 
 
 
 
67% 
19 
 
 
 
75% 
  38 
20 
 
 
 
72% 
21 
 
 
 
78% 
We then explored this method by replacing simple aldehydes with 2-formyl 
phenylboronic acid 5. Due to the presence of borinic acid group ortho to 
aldehyde, we expected that 5 could self-catalyze the reaction with isonitrile. To 
our surprise, the reaction progressed and benzoxoborole was formed in 84% 
yield by dehydration. This was evident by the characteristic peak of B-OH at 
~9ppm in 1H-NMR.  
In a similar way, benzoboroxoles 6b and 6c were obtained upon reaction 
of 5 with isonitriles 2b and 2c respectively (Scheme 3.1).  Also, products 6a-I 
were synthesized by the reaction of aldehydes 5a-c with isonitriles 2a-c 
(Scheme 3.1).31   
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Scheme 3.1: Synthesis of functionalized benzoxaboroles. 
The above synthesized structural entities can be utilized in the 
applications of material chemistry as well as synthetic chemistry as these 
compounds act as intermediates for Suzuki cross coupling reactions.32  
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Experimental Procedures 
1. Representative procedure for the preparation of hydroxyamide 4a:  To a 
stirred solution of propion-aldehyde 1a (0.14 mL, 2.0 mmol) in 2mL DMF was 
added benzyl isonitrile 2a (0.24 mL, 2.0 mmol), and boric acid (0.12 g, 2.0 mmol) 
and stirred overnight at room temperature.  Upon completion (TLC), the reaction 
mixture was worked up with water and diethyl ether (3 x 25 mL).  The combined 
organic layers were dried (MgSO4), concentrated in vacuo, and purified by 
column chromatography (silica gel, hexane:acetone, 4:1) to obtain 0.30 g (78%) 
of hydroxy amide 4a.  1H NMR (500 MHz, CDCl3): 7.22-7.32 (m, 5H), 7.18 (bs, 
1H), 4.47 (t, J = 4.5 Hz, 1H), 4.42 (dd, J = 4.0, 15.0 Hz, 1H), 4.36 (dd, J = 4.0, 
15.0 Hz, 1H),4.05-4.08 (m, 1H), 1.78-1.90 (m, 1H), 1,62-1.72 (m, 1H), 0.95 (t, J = 
7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3): 174.5, 138.2, 128.9, 127.9, 127.7, 73.2, 
43.3, 28.1, 9.4; ESI-MS: 216 [(M+Na)+, 100%], 194 (M+H)+. 
2. Represenative procedure for the preparation of benzoxaborole 6c: To a 
stirred solution of boronoaldehyde 5 (0.3 g, 2.0 mmol) in 2mL DMF was added 
tert-butyl isonitrile (0.23 mL, 2.0 mmol), and stirred overnight at room 
temperature.  Upon completion (TLC), the reaction mixture was worked up with 
water and ethyl acetate (3 x 25 mL).  The combined organic layers were dried 
(MgSO4), concentrated in vacuo, and purified by column chromatography (silica 
gel, hexane:ethyl acetate, 3:1) to obtain 0.30 g (65%) of benzoxaborole  6c. 
(Found: C, 61.53; H, 8.10; N, 6.02 %; C12H16BNO3 requires: C, 61.84; H, 6.92; N, 
6.01%); 1H NMR (500 MHz, DMSO-d6): 9.33 (bs, 1H), 7.67 (d, J = 7.2 Hz, 1H), 
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7.62 (d, J = 7.6 Hz, 1H), 7.36 (t, J = 7.4 Hz, 1H), 7.26 (t, J = 7.4 Hz, 1H), 6.52 (s, 
1H), 5.27 (s, 1H), 1.21 (s, 9H); 13C NMR (125 MHz, CDCl3): 169.4, 152.3, 131.3, 
130.8, 128.1, 122.9, 80.2, 51.1, 28.9; ESI-MS: 232 [(M-H)+, 100%]. 
Conclusions  
 In conclusion, we have introduced a novel methodology for the synthesis of α-
hydroxyamides using boric acid as catalyst upon the α-addition of isonitriles to 
aldehydes. We have also extended this protocol for the synthesis of 
functionalized benzoxaboroles via intramolecular cyclization utilized Passerini 
type multicomponent coupling reaction. These synthesized compounds act as 
excellent synthons and intermediates for the applications in organic and 
medicinal chemistry.  
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Overall conclusion 
  As these compounds did not exhibit any antimicrobial efficacy or cytotoxicity, 
they can be used for boron neutron capture therapy (BNCT) since this these 
compounds mimic glycolytic metabolites such as fructose.  
  Boron neutron capture therapy is a binary therapy in which, the tumor cells 
are loaded with high concentration of 10B and later activated by applying a 
radiation field of low energy neutrons. 10B is non-radioactive and is present in 
20% of natural boron. Neutron capture results in the formation of excited 11B 
nuclei, which then undergo fission to produce high linear energy transfer (LET) 
particles such as α- (4He2), 7Li3 and γ-particles. Cell death is triggered by the 
release of these heavily charged particles (He and Li) that create ionization 
tracks along their trajectories.  
       
10B5 + 1n0  ------------->  4He2 +  7Li3  +  2.3 MeV 
 Binding studies and boron accumulation studies have to be carried out to 
determine the potency of these compound for their use in BNCT. 
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Spectral Characterization 
 
7a 
Methyl 2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)acrylate 7a: yield 
= 58% 
1H NMR (500MHz, DMSO-d6) δ 9.39 (s, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.46 (t, J = 
7.5 Hz, 1H), 7.37 (t, J = 7 Hz, 1H), 7.30 (d, J = 7.5 Hz, 1H), 6.20 (s, 1H), 5.98 (s, 
1H), 5.84 (s, 1H), 3.72 (s, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 166.2, 155.6, 140.8, 131.5, 131.3, 128.1, 
126.6, 122.3, 79.3, 52.6 
 
7b 
Methyl 2-(1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-
yl)acrylate 7b: yield = 54% 
  44 
1H NMR (500MHz, DMSO-d6) δ 9.19 (s, 1H), 7.63 (d, J = 8 Hz, 1H), 6.94 (d, J = 8 
Hz, 1H), 6.80 (s, 1H), 6.19 (s, 1H), 5.89 (s, 1H), 5.81 (s, 1H), 3.76 (s, 3H), 3.72 
(s, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 166.3, 162.5, 157.9, 140.8, 132.6, 126.6, 
115.1, 107.2, 78.8, 55.8, 52.6 
 
7c 
Methyl 2-(5-ethoxy-4-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-
yl) acrylate 7c: yield = 56% 
1H NMR (500MHz, DMSO-d6) δ 9.37 (s, 1H), 7.52 (d, J = 7 Hz, 1H), 7.19 (t, J = 5 
Hz, 1H), 6.22 (s, 1H), 6.04 (s, 1H), 5.89 (s, 1H), 4.17 (q, J = 6 Hz, 2H), 3.70 (s, 
3H), 1.38 (t, J = 6 Hz, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 165.8, 144.3, 142.8, 140.6, 139.3, 128.6, 
127.7, 115.9, 76.8, 65.3, 52.6, 15.3 
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7e 
Phenyl 2-(1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl) 
acrylate 7e: yield = 48% 
1H NMR (500MHz, DMSO-d6) δ 9.24 (s, 1H), 7.66 (d, J = 8 Hz, 1H), 7.44 (t, J = 8 
Hz, 2H), 7.29 (t, J = 7 Hz, 1H), 7.12 (d, J = 9 Hz, 2H), 6.96 (d, J = 8.5 Hz, 1H), 
6.88 (s, 1H), 6.49 (s, 1H), 6.08 (s, 1H), 6.00 (s, 1H), 3.78 (s, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 164.5, 162.6, 157.9, 150.9, 140.2, 132.6, 
130.3, 129.2, 126.8, 122.3, 115.3, 107.1, 79.1, 55.9 
 
7f 
Phenyl 2-(5-ethoxy-4-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-
yl) acrylate 7f: yield = 41% 
1H NMR (500MHz, DMSO-d6) δ 9.40 (s, 1H), 7.50 (d, J = 8 Hz, 3H), 7.44 (t, J = 8 
Hz, 2H), 7.30 (t, J = 8 Hz, 1H), 7.25 (t, J = 7.5 Hz, 1H), 7.08 (d, J = 8.5 Hz, 2H), 
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6.55 (s, 1H), 6.18 (s, 1H), 6.08 (s, 1H), 4.187(q, J = 7 Hz, 2H), 1.37 (t, J = 7 Hz, 
3H) 
13C NMR (125 MHz, DMSO-d6) δ 164.1, 150.8, 138.9, 130.9, 130.3, 126.8, 
122.3, 116.0, 77.0, 65.4, 15.3 
 
7g 
2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)acrylonitrile 7g: yield = 
69% 
1H NMR (500MHz, DMSO-d6) δ 9.63 (s, 1H), 7.80 (d, J = 7 Hz, 1H), 7.56 (t, J = 7 
Hz, 1H), 7.46 (t, J = 7 Hz, 1H), 7.35 (d, J = 8 Hz, 1H), 6.49 (s, 1H), 6.32 (s, 1H), 
5.87 (s, 1H) 
13C NMR (125 MHz, DMSO-d6) δ 153.0, 134.3, 131.8, 131.2, 128.8, 124.0, 
122.4, 116.5, 80.2 
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7h 
2-(1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)acrylonitrile 
7h: yield = 62% 
1H NMR (500MHz, DMSO-d6) δ 9.42 (s, 1H), 7.67 (d, J = 8 Hz, 1H), 7.01 (d, J = 
7.5 Hz, 1H), 6.85 (s, 1H), 6.47 (s, 1H), 6.32 (s, 1H), 5.78 (s, 1H), 3.80 (s, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 162.9, 155.8, 134.6, 132.8, 124.2, 116.8, 
116.3, 107.1, 80.1, 56.0 
 
7i 
2-(5-ethoxy-4-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-
yl)acrylonitrile 7i: yield = 54% 
1H NMR (500MHz, DMSO-d6) δ 9.65 (s, 1H), 7.54 (d, J = 7.5 Hz, 1H), 7.29 (t, J = 
7.5 Hz, 1H), 6.50 (s, 1H), 6.39 (s, 1H), 6.01 (s, 1H), 4.18 (q, J = 7.5 Hz, 2H), 1.36 
(t, J = 7 Hz, 1H) 
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13C NMR (125 MHz, DMSO-d6) δ 149.5, 149.2, 148.0, 145.0, 139.3, 139.2, 
135.6, 128.2, 128.1, 122.9, 117.0, 116.5, 79.9, 77.6, 65.5, 15.2 
 
7j 
3-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)but-3-en-2-one 7j: yield 
= 49% 
1H NMR (500MHz, DMSO-d6) δ 9.38 (s, 1H), 7.73 (d, J =  7.5 Hz, 1H), 7.43 (t, J = 
7.5 Hz, 3H), 7.35 (t, J = 7 Hz, 1H), 7.20 (d, J = 7 Hz , 1H), 6.28 (s, 1H), 6.05 (s, 
1H), 5.90 (s, 1H), 2.39 (s, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 199.9, 156.4, 148.4, 131.5, 131.3, 128.0, 
126.8, 122.5, 78.1, 27.3 
 
7k 
3-(1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)but-3-en-2-
one 7k: yield = 44% 
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1H NMR (500MHz, DMSO-d6) δ 9.19 (s, 1H), 7.63 (d, J = 8 Hz, 1H), 6.92 (d, J = 8 
Hz, 1H), 6.72 (s, 1H), 6.28 (s, 1H), 6.98 (s, 1H), 5.89 (s, 1H), 3.74 (s, 1H), 2.40 
(s, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 200.0, 162.5, 158.8, 148.5, 132.6, 126.8, 
115.0, 107.4, 77.7, 55.8, 27.3 
 
7m 
2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)cyclohex-2-en-1-one 
7m: yield = 56% 
1H NMR (500MHz, DMSO-d6) δ 9.30 (s, 1H), 7.71 (d, J = 7 Hz, 1H), 7.42 (t, J = 7 
Hz, 1H), 7.33 (t, J = 7 Hz, 1H), 7.22 (d, J = 7 Hz, 1H), 6.82 (t, J = 4 Hz, 1H), 5.98 
(s, 1H), 2.42 (t, J = 7 Hz, 2H), 2.34 (m, 2H), 1.89 (m, 2H) 
13C NMR (125 MHz, DMSO-d6) δ 198.7, 157.0, 147.1, 139.0, 131.5, 131.1, 
127.8, 122.5, 77.4, 25.8, 22.9 
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13a 
Methyl 2-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)methyl)acrylate 
13a: yield = 75% 
1H NMR (500MHz, DMSO-d6) δ 9.17 (s, 1H), 7.71 (d, J = 7 Hz, 1H), 7.48 (t, J = 
7.5 Hz, 1H), 7.40 (d, J = 7.5 Hz, 1H), 7.35 (t, J = 7.5 Hz, 1H), 6.17 (s, 1H), 5.76 
(s, 1H), 5.31 (dd, J = 7 Hz, 1H), 3.98 (s, 3H), 2.94 (d, J = 14.5, 1H), 2.43 (dd, J = 
8.5 Hz, 1H) 
13C NMR (125 MHz, DMSO-d6) δ 167.7, 157.4, 156.8, 137.1, 131.2, 128.2, 
127.9, 122.2, 79.2, 52.5, 
 
13b 
methyl 2-((1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-
yl)methyl) acrylate 13b: yield = 72% 
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1H NMR (500MHz, DMSO-d6) δ 8.96 (s, 1H), 7.58 (d, J = 8 Hz, 1H), 6.94 (s, 1H), 
6.91 (d, J = 8 Hz, 1H), 6.16 (s, 1H), 5.76 (s, 1H), 5.22 (dd, J = 4 Hz, 1H), 3.80 (s, 
3H), 3.70 (s, 3H), 2.94 (dd, J = 6 Hz, 1H), 2.40 (dd, J =, 1H) 
13C NMR (125 MHz, DMSO-d6) δ 167.6, 162.4, 159.4, 137.2, 132.4, 128.1, 
115.3, 106.8, 78.8, 55.9, 52.5 
 
13c 
Methyl 2-((5-ethoxy-4-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-
yl) methyl)acrylate 13c: yield = 69% 
1H NMR (500MHz, DMSO-d6) δ 9.19 (s, 1H), 7.43 (d, J = 8 Hz, 1H), 7.17 (t, J = 7 
Hz, 1H), 6.14 (s, 1H), 5.71 (s, 1H), 5.44 (dd, J = 2.5, 8, 1H), 4.15 (q, J = 6.5 Hz, 
2H), 3.66 (s, 3H), 3.03 (d, J = 12 Hz, 1H), 2.47 (dd, J = 8.5 Hz, 14.5, 1H), 1.36 (t, 
J = 6 Hz, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 167.4, 149.1, 147.7, 145.8, 142.6, 142.5, 
136.6, 128.6, 127.7, 115.9, 76.5, 65.3, 52.5, 15.3 
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13d 
Methyl 3-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)-2-methylene 
butanoate 13d: yield = 76% 
1H NMR (500MHz, DMSO-d6) δ 9.24(s, 1H), 7.73 (d, J = 8 Hz, 1H), 7.48 (t, J = 6 
Hz, 1H), 7.36 (t, J = 7 Hz, 2H), 6.30 (s, 1H), 5.84 (s, 1H), 5.28 (s, 1H), 3.75 (s, 
3H), 3.16(q, J = 3.5, 1H), 0.67 (d, J = 7 Hz, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 167.7, 156.0, 143.0, 131.5, 131.1, 127.4, 
126.4, 121.9, 81.9, 52.7, 39.7, 39.3, 12.4 
O
B
OH
O
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13e 
Methyl 3-(1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)-2-
methylenebutanoate 13e: yield = 74% 
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1H NMR (500MHz, DMSO-d6) δ 9.02 (s, 1H), 7.61 (d, J = 8 Hz, 1H), 6.93 (dd, J = 
2, 8 Hz, 1H), 6.89 (s, 1H), 6.29 (s, 1H), 5.85 (s, 1H), 5.21 (d, J = 3 Hz, 1H), 3.81 
(s, 3H), 3.76 (s, 3H), 3.17-3.3.13 (m, 1H), 0.68 (d, J = 7 Hz, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 167.7, 162.6, 158.6, 143.1, 132.4, 126.3, 
115.2, 106.5, 81.6, 55.9, 52.7, 39.2, 31.4, 12.3 
 
15a 
2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)-1-phenylethan-1-one 
15a: yield = 60% 
1H NMR (500MHz, DMSO-d6) δ  9.20 (s, 1H), 8.03 (dd,  J = 1, 7.5, 2H),  7.74 (d,  
J = 7.5, 1H),  7.68-7.65 (m, 1H), 7.56-7.48 (m, 4H), 7.40-7.37 (m, 1H), 5.71 (dd, J 
= 3.75, 8.75, 1H), 3.63-3.55 (m, 1H), 3.38-3.33 (m 1H) 
13C NMR (125 MHz, DMSO-d6) δ 198.1, 157.0, 137.2, 133.8, 131.2, 130.9, 
130.8, 129.2, 128.7, 127.7, 122.0, 77.3, 70.6, 45.8 
 
15c 
1-(4-bromophenyl)-2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-
yl)ethan-1-one 15c: yield = 45% 
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1H NMR (500MHz, DMSO-d6) δ  9.2 (s, 1H), 7.95 (d, J = 8, 2H), 7.76-7.72 (m, 
3H), 7.51-7.38 (m, 3H), 5.68 (dd, J = 3.5, 5, 1H), 3.58 (dd, J = 3.5, 17, 1H), 3.33 
(dd, J = 9, 17, 1H) 
13C NMR (125 MHz, DMSO-d6) δ 197.0, 157.1, 153.6, 142.4, 132.6, 131.1, 
130.9, 127.7, 122.1, 106.3, 77.3, 60.6, 56.5, 45.6 
 
15d 
2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)-1-(3,4,5-
trimethoxyphenyl)ethan-1-one 15d: yield = 47% 
1H NMR (500MHz, DMSO-d6) δ  9.2 (s, 1H), 7.74 (d, J = 7, 1H), 7.52 (t,  J =  
7.75, 2H), 7.38 (t,  J = 7, 1H), 7.31 (s, 2H), 5.71 (dd, J = 4, 8.5, 1H), 3.86 (s, 3H), 
3.76 (s, 6H), 3.47 (m, 2H) 
13C NMR (125 MHz, DMSO-d6) δ 197.0, 157.1, 153.3, 142.4, 132.6, 131.1, 
130.9, 127.7, 122.1, 106.3, 77.3, 60.6, 56.5, 45.6 
 
1 
N-benzyl-2-hydroxybutanamide 1: yield = 78% 
  55 
13C NMR (125 MHz, CDCl3) δ 174.5, 138.2, 129.0, 127.9, 127.8, 73.2, 43.3, 28.0, 
9.4 
 
2 
N-(tert-butyl)-2-hydroxybutanamide 2: yield = 74% 
1H NMR (500MHz, CDCl3) δ 6.67 (br, s, 1H), 4.53 (d, J = 5 Hz, 1H), 3.90 (m, 1H), 
1.78 (m, 1H), 1.64 (m, 1H), 1.32 (s, 9H), 0.91(t J = 8 Hz) 
13C NMR (125 MHz, CDCl3) δ 174.0, 73.0, 51.0, 28.8, 27.9, 9.1  
 
3 
N-cyclohexyl-2-hydroxybutanamide 3: yield = 75% 
1H NMR (500MHz, CDCl3) δ 6.59 (br, d, 1H), 4.03 (t, J = 3.5, 1H), 3.72 (m, 2H), 
1.86 (m, 4H), 1.65 (m, 4H), 1.18 (m, 3H), 0.96 (t, J = 7 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 173.3, 73.0, 48.1, 33.3, 28.1, 25.7, 25.0, 9.2 
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4 
N-benzyl-2-hydroxy-3-methylbutanamide 4: yield = 70% 
1H NMR (500MHz, CDCl3) δ 7.35-7.28 (m, 5H), 7.00 (br, s 1H), 4.46 (dd, J = 6 
Hz, 2H), 4.02 (s, 1H), 2.20 (m, 1H), 1.03 (d, J = 7 Hz, 3H), 0.87 (d, J = 7 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 173.7, 138.3, 129.0, 128.0, 127.8, 76.6, 43.4, 32.1, 
19.4, 15.8 
 
5 
N-(tert-butyl)-2-hydroxy-3-methylbutanamide 5: yield = 71% 
1H NMR (500MHz, CDCl3) δ 6.53(br, s, 1H), 3.92(d, J = 5.5 Hz, 1H), 3.80(m, 1H), 
2.10(m, 1H), 1.35(s, 9H), 0.99(d, J = 6.5 Hz, 3H), 0.84(d, J =7 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 173.3, 76.3, 51.1, 32.0, 29.0, 19.5, 15.6 
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6 
N-cyclohexyl-2-hydroxy-3-methylbutanamide 6: yield = 74% 
1H NMR (500MHz, CDCl3) δ 6.57 (br, d, J = 7.5 Hz, 1H), 3.90 (d, J = 8 Hz, 1H), 
3.76 (m, 1H), 3.59 (d, J = 5 Hz,  1H), 2.14 (m, 1H), 1.89 (m, 2H), 1.71 (m, 2H), 
1.61 (m, 1H), 1.36 (m, 2H), 1.16 (m, 3H), 1.01 (d, J = 7 Hz, 3H), 0.84 (d, J =  6.5, 
3H) 
13C NMR (125 MHz, CDCl3) δ 172.9, 76.2, 48.0, 33.4, 33.2, 32.1, 25.7, 25.0, 
19.4, 15.6 
 
7 
N-benzyl-2-hydroxy-3,3-dimethylbutanamide 7: yield = 61% 
1H NMR (500MHz, CDCl3) δ 7.33-7.28 (m, 5H), 6.81 (br, s, 1H), 4.44 (dd, J = 5.5 
Hz, 2H), 3.74 (d, J = 5 Hz, 1H), 3.51 (d, J = 5.5 Hz, 1H), 0.90 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 173.0, 138.3, 128.9, 128.0, 127.7, 79.8, 43.4, 35.4, 
26.3 
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9 
N-cyclohexyl-2-hydroxy-3,3-dimethylbutanamide 9: yield = 72% 
1H NMR (500MHz, CDCl3) δ 6.08 (br, s, 1H), 3.80 (br, 1H), 3.65 (d, J = 6 Hz, 1H), 
3.18 (d, J = 5.5 Hz, 1H), 1.90 (m, 2H), 1.73-1.61 (m, 2H), 1.42-1.16 (m, 6H), 0.99 
(s, 9H) 
 
10 
(E)-N-benzyl-2-hydroxypent-3-enamide 10: yield = 78% 
1H NMR (500MHz, CDCl3) δ 7.36-7.26 (m, 5H), 6.82 (br, s, 1H), 5.88 (dd, J = 6.5 
Hz, 1H), 5.60 (dd, J = 7 Hz, 1H), 4.53 (d, J = 7 Hz, 1H), 4.45 (d, J = 6 Hz, 2H), 
3.71 (br, s, 1H), 1.74 (d, J = 6.5 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 172.8, 138.0, 131.0, 129.1, 129.0, 127.9, 127.8, 
73.18, 43.6, 18.0 
 
11 
(E)-N-(tert-butyl)-2-hydroxypent-3-enamide 11: yield = 74% 
  59 
1H NMR (500MHz, CDCl3) δ 5.99(br, s, 1H), 5.88(m, 1H), 5.54(dd, J = 7.5 Hz, 
1H), 4.35(d, J =11 Hz, 3.39(d, J =3.5 Hz, 1H), 1.77(d, 7.5 Hz, 3H), 1.37(s, 9H) 
13C NMR (125 MHz, CDCl3) δ 171.7, 131.3, 129.6, 73.3, 51.6, 29.0, 18.0 
 
12 
(E)-N-cyclohexyl-2-hydroxypent-3-enamide 12: yield = 72% 
1H NMR (500MHz, CDCl3) δ 5.88 (br, s, 1H) 5.81 (dd,J = 6.5 Hz, 1H), 5.47 (dd, J 
= 7.5 Hz,1H), 4.36 (d,J = 7.5 Hz, 1H), 3.70(m, 1H), 1.84 (d, J =12.5, 3H), 1.69 (d, 
J =6.5, 3H), 1.67-0.76 ( m, 8H) 
13C NMR (125 MHz, CDCl3) δ 171.5, 131.3, 129.4, 73.1, 48.6, 33.3, 25.7, 25.0, 
18.0 
 
13 
N-benzyl-2-hydroxy-2-phenylacetamide 13: yield = 80% 
  60 
1H NMR (500MHz, CDCl3) δ 7.34-7.12(m, 10H), 4.95(s, 1H), 4.65(br, s, 1H), 
4.31(s, 2H) 
13C NMR (125 MHz, CDCl3) δ 172.0, 139.9, 138.0, 128.9, 128.6, 128.0, 127.8, 
127.7, 127.0, 74.4, 43.5 
 
14 
N-(tert-butyl)-2-hydroxy-2-phenylacetamide 14: yield = 76% 
1H NMR (500MHz, CDCl3) δ 7.36-7.29 (m, 5H), 6.21 (br, s, 1H), 4.84 (s, 1H), 
4.22 (br, s, 1H), 1.31 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 171.5, 140.1, 129.1, 128.8, 127.1, 74.5, 51.7, 28.8 
 
 
15 
N-cyclohexyl-2-hydroxy-2-phenylacetamide 15: yield = 80% 
  61 
1H NMR (500MHz, CDCl3) δ 7.25 (m, 5H), 6.31 (s, 1H), 4.81 (s, 1H), 4.22 (s, 1H), 
3.61 (m, 1H), 1.73-0.71 (m, 10H)  
13C NMR (125 MHz, CDCl3) δ 140.2, 128.8, 128.4, 127.0, 74.2, 48.4, 33.0, 32.9, 
25.7, 25.0 
 
16 
N-benzyl-2-(furan-2-yl)-2-hydroxyacetamide 16: yield = 65% 
1H NMR (500MHz, CDCl3) δ7.32 (d, J = 2 HZ 1H), 7.27-7.12 (m, 5H), 6.54 (br s, 
1H), 6.30 (d, J =20, 2H), 5.08(s, 1H), 4.43 (m, 2H), 3.63(br, 1H),  
13C NMR (125 MHz, CDCl3) δ 170.4, 152.0, 143.2, 137.8, 129.0, 127.9, 127.8, 
110.8, 108.9, 68.1, 43.7 
 
17 
N-(tert-butyl)-2-(furan-2-yl)-2-hydroxyacetamide 17: yield = 68% 
1H NMR (500MHz, CDCl3) δ 7.412(t, J = 1 Hz, 1H), 6.37(d, J = 3 Hz, 2H), 
6.10(br, s, 1H), 5.00(s, 1H), 3.96(br, s, 1H), 1.37(s, 9H) 
  62 
13C NMR (125 MHz, CDCl3) δ169.0, 152.5, 143.1, 110.8, 108.5, 68.0, 51.9, 28.9 
 
18 
N-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetamide 18: yield = 67% 
1H NMR (500MHz, CDCl3) δ 7.41 (d, J = 1.5 Hz, 1H), 6.40-6.37 (m, 2H), 6.2 (d, J 
= 3.5 Hz, 1H), 3.92(br, s, 1H), 3.84-3.78 (m, 1H), 1.95-187 (m, 2H), 1.77-1.60 (m, 
4H), 1.42-1.33 (m, 2H), 1.27-1.14 (m,3H) 
13C NMR (125 MHz, CDCl3) δ 169.0, 152.2, 143.1, 110.9, 108.6, 67.9, 48.9, 33.1 
25.7, 24.9 
 
19 
N-benzyl-2-hydroxy-2-(thiophen-2-yl)acetamide 19: yield = 75% 
1H NMR (500MHz, CDCl3) δ 7.28 (m, 6H), 7.07 (d, J = 3.5, 1H), 7.04 (br, s, 1H), 
6.95 (t, J = 5 Hz, 1H), 5.30 (s, 1H), 4.65 (br, s, 1H), 4.41 (t, J = 5.5 Hz, 2H)  
13C NMR (125 MHz, CDCl3) δ 171.8, 161.7, 142.9, 137.8, 129.0, 128.0, 127.9, 
127.1, 126.1, 70.4, 43.7 
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20 
N-(tert-butyl)-2-hydroxy-2-(thiophen-2-yl)acetamide 20: yield = 72% 
1H NMR (500MHz, CDCl3) δ 7.28(d, J = 5.5 Hz, 1H), 7.06(d, J = 4.5 Hz, 1H), 
6.98(t, J = 4.5 Hz, 1H), 6.34(br,s, 1H), 5.13(s,1H), 4.48(br, s, 1H),1.35(s, 9H) 
13C NMR (125 MHz, CDCl3) δ 170.7, 143.3, 127.0, 126.1, 126.0, 70.4, 51.7, 28.8 
 
21 
N-cyclohexyl-2-hydroxy-2-(thiophen-2-yl)acetamide 21: yield = 78% 
1H NMR (500MHz, CDCl3) δ 7.31 (d, J = 4 Hz, 1H), 7.11 (d, J = 3.5, 1H), 7.00(t, J 
= 3 Hz,1H), 6.25 (br, d, J =6.5, 1H), 4.09 (d, J = 4 Hz, 1H), 3.80 (m, 1H), 1.91-
1.90 (m, 2H), 1.73-1.60 (m,3H), 1.41-1.32(m,2H), 1.21-1.16(m, 2H) 
13C NMR (125 MHz, CDCl3) δ 171.2, 143.0,127.1, 126.3, 126.2, 70.2, 48.8, 33.0, 
25.7, 24.9 
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6a 
N-benzyl-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-3-carboxamide 6a: 
yield = 81% 
1H NMR (500MHz, DMSO-d6) δ 9.55 (s, 1H), 8.57 (t, J = 8 Hz, 1H), 7.76 (d, J = 7 
Hz, 1H), 7.56 (d, J = 7.5 Hz, 2H), 7.49 (t, J = 7 Hz, 1H), 7.41 (t, J = 7.5 Hz, 2H), 
7.30-7.19 (m, 3H), 5.56 (s, 1H), 4.31 (dd, J = 6.5 Hz, 1H), 4.22 (dd, J = 6 Hz, 1H) 
13C NMR (125 MHz, DMSO-d6) δ 170.2, 153.1, 140.0, 131.6, 131.2, 128.9, 
128.5, 127.9, 127.5, 122.6, 80.4, 42.6 
 
6b 
N-cyclohexyl-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-3-carboxamide 
6b: yield = 76% 
1H NMR (500MHz, DMSO-d6) δ 9.42 (br, s, 1H), 7.82 (d, J = 8 Hz, 1H), 7.76 (d, J 
= 7.5 Hz, 1H), 7.51-7.38 (m, 3H), 5.42 (s, 1H), 3.56 (m, 1H), 1.79-0.85  (m, 10H) 
  65 
13C NMR (125 MHz, DMSO-d6) δ 168.9, 153.3, 131.5, 131.1, 128.3, 122.3, 80.2, 
79.9, 48.3, 32.9, 32.8, 25.8, 25.4, 25.3 
 
6c 
N-(tert-butyl)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-3-carboxamide 
6c: yield = 65% 
1H NMR (500MHz, DMSO-d6) δ 9.42 (br, s, 1H), 7.71 (d, J = 7 Hz, 1H), 7.56-7.45 
(m, 3H), 7.40-7.38 (m, 1H), 5.42 (s, 1H), 1.24 (s, 9H) 
13C NMR (125 MHz, DMSO-d6) δ 169.1, 153.4, 131.4, 131.0, 128.3, 122.3, 80.3, 
79.9, 51.0, 29.1 
 
6d 
N-benzyl-1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborole-3-
carboxamide 6d: yield = 61% 
  66 
1H NMR (500MHz, DMSO-d6) δ 9.36(s, 1H), 8.56 (t, J = 6 Hz, 1H), 7.65 (d, J = 8 
Hz, 1H), 7.25 (m, 5H), 7.06 (d, J = 2.5, 1H), 6.97 (dd, J = 2.5, 8.5, 1H), 5.49 (s, 
1H), 4.36 (dd, J = 6.5 Hz, 15, 1H), 4.19 (dd, J = 6 Hz, 15, 1H), 3.78 (s, 3H) 
13C NMR (125 MHz, DMSO-d6) δ 170.1, 162.5, 155.5, 140.1, 132.5, 128.9, 
128.0, 127.5, 115.8, 107.0, 80.1, 55.9, 42.6 
 
6e 
N-cyclohexyl-1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborole-3-
carboxamide 6e: yield = 55% 
1H NMR (500MHz, DMSO-d6) δ 9.30 (s, 1H), 7.84 (d, J = 8 Hz, 1H), 7.63 (d, J = 8 
Hz, 1H), 7.03 (s, 1H), 6.95 (d, J = 8 Hz, 1H), 6.40 (s, 1H), 3.78 (s, 3H), 3.55 (br, 
s, 1H), 1.71-1.53 (m, 5H), 1.27-1.09 (m, 6H) 
13C NMR (125 MHz, DMSO-d6) δ 168.9, 162.4, 155.7, 132.4, 115.5, 107.0, 79.9, 
55.9, 48.2, 32.9, 32.8, 25.8, 25.4 
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6f 
N-(tert-butyl)-1-hydroxy-5-methoxy-1,3-dihydrobenzo[c][1,2]oxaborole-3-
carboxamide 6f: yield = 54% 
1H NMR (500MHz, DMSO-d6) δ 9.28 (s, 1H), 7.63 (d, J = 8 Hz, 1H), 7.4 (s, 1H),  
7.03 (s, 1H), 6.96 (dd, J = 2 HZ 8, 1H), 5.34 (s, 1H), 3.79 (s, 3H), 1.28 (s, 9H) 
13C NMR (125 MHz, DMSO-d6) δ 169.1, 162.4, 155.7, 132.4, 115.3, 107.1, 79.9, 
55.9, 51.0, 29.1 
 
6g 
N-benzyl-5-ethoxy-4-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-3-
carboxamide 6g: yield = 54% 
  68 
1H NMR (500MHz, DMSO-d6) δ 9.45 (s, 1H), 8.86 (t, J = 6 Hz, 1H), 7.47 (d, J = 8 
Hz, 1H), 7.33-7.25 (m, 6H), 5.68 (s, 1H), 4.39-4.07 (m, 4H), 1.36 4.19 (t, J = 6.7, 
3H) 
13C NMR (125 MHz, DMSO-d6) δ 168.7, 139.7, 129.0, 127.9, 127.6, 127.6, 
116.2, 78.1, 65.4, 42.9, 15.3 
 
6h 
N-cyclohexyl-5-ethoxy-4-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2] 
oxaborole-3-carboxamide 6h: yield = 58% 
1H NMR (500MHz, DMSO-d6) δ 9.38 (s, 1H), 8.31 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 
7.5 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 5.60 (s, 1H), 4.13 (q, J =7, 2H), 3.53 (br, d, J 
= 7.5 Hz, 1H), 1.72-1.13 (m, 13H) 
13C NMR (125 MHz, DMSO-d6) δ 167.4, 149.2, 149.1, 147.7, 145.7, 139.7, 
127.5, 115.9, 77.8, 65.3, 48.3, 32.9, 31.4, 25.9, 25.2, 15.3 
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6i 
N-(tert-butyl)-5-ethoxy-4-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2] 
oxaborole-3-carboxamide 6i: yield = 49% 
1H NMR (500MHz, DMSO-d6) δ 9.35 (s, 1H), 8.09 (s, 1H), 7.45 (d, J = 8 Hz, 1H), 
7.2 (t, J = 8, 1H), 5.62 (s, 1H), 4.13 (q, J = 7 Hz, 1H),1.36 (t, J = 7 Hz, 3H), 1.28 
(s, 9H) 
13C NMR (125 MHz, DMSO-d6) δ 167.7, 149.2, 149.0, 139.8, 127.5, 115.9, 78.0, 
65.3, 51.1, 29.0, 15.3 
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